Wall Street Zen downgraded shares of Palatin Technologies (NASDAQ:PTN – Free Report) from a sell rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.
Several other analysts have also commented on PTN. HC Wainwright started coverage on Palatin Technologies in a research note on Friday, November 6th. They issued a “buy” rating and a $12.00 price target on the stock. Zacks Research started coverage on Palatin Technologies in a report on Friday, November 6th. They set a “hold” rating for the company. Finally, Weiss Ratings assumed coverage on shares of Palatin Technologies in a research note on Wednesday, November 4th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $12.00.
Read Our Latest Analysis on Palatin Technologies
Palatin Technologies Trading Down 7.1%
Shares of Palatin Technologies stock opened at $4.58 on Friday. Palatin Technologies has a twelve month low of $4.51 and a twelve month high of $31.00. The stock has a market cap of $8.15 million, a PE ratio of -0.81 and a beta of 0.75.
Palatin Technologies (NASDAQ:PTN – Get Free Report) last released its quarterly earnings data on Monday, September 28th. The company reported ($1.11) earnings per share for the quarter. Palatin Technologies had a negative net margin of 385.38% and a negative return on equity of 235.46%. The company had revenue of $0.30 million during the quarter. Research analysts forecast that Palatin Technologies will post -3.24 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Palatin Technologies stock. State Street Corp bought a new position in Palatin Technologies (NASDAQ:PTN – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 14,000 shares of the company’s stock, valued at approximately $124,000. State Street Corp owned approximately 0.79% of Palatin Technologies at the end of the most recent reporting period. 11.50% of the stock is currently owned by institutional investors.
About Palatin Technologies
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications. The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Recommended Stories
- Five stocks we like better than Palatin Technologies
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
